Please login to the form below

Not currently logged in
Email:
Password:

Rajesh Chopra joins board of e-Therapeutics

VP of translational and early drug development at Celgene joins as e-Therapeutics prepares to advance several investigational drugs into clinical trials

Dr Rajesh Chopra is to join the board of e-Therapeutics as a non-executive director.

He serves as VP of translational and early drug development at Celgene and joins UK-based drug discovery and development company e-Therapeutics as it prepares to advance several investigational drugs into clinical trials.

Prior to his current role at Celgene, where he is leading efforts to integrate drug discovery and clinical development at Celgene sites in the US and Europe, Chopra spent five years at AstraZeneca (AZ).

During his time at AZ he eventually held the role of medical science director, senior principal scientist and disease area team leader for blood cancers.

Chopra has also held positions outside pharma, working as a clinician and academic in the UK, and spent seven years as clinical director of the Department of Haematological Oncology at the Christie Hospital in Manchester. He is also a a Fellow of both the Royal College of Physicians and the Royal College of Pathologists in the UK.

Professor Oliver James, chair of e-Therapeutics, said: “Rajesh's appointment represents a further significant strengthening of our Board. He brings highly relevant senior-level experience gained in world-leading pharma and biotech companies and substantial expertise in oncology.

“His input will be of great value as we advance our clinical programmes and bring more new drugs through into development from our discovery operation.”

7th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics